Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLDX Celldex Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CLDX
Price (delayed)
$22
Market cap
$1.46B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.7
Enterprise value
$1.45B
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which
Highlights
Celldex Therapeutics's revenue has increased by 24% YoY and by 8% from the previous quarter
The company's gross profit rose by 24% YoY and by 8% QoQ
The debt has soared by 62% YoY but it has decreased by 10% QoQ
CLDX's quick ratio is down by 33% year-on-year but it is up by 15% since the previous quarter
Celldex Therapeutics's net income has decreased by 23% YoY and by 13% from the previous quarter
Celldex Therapeutics's equity has decreased by 16% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of CLDX
Market
Valuations
Earnings
Shares outstanding
66.39M
Market cap
$1.46B
Enterprise value
$1.45B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.08
Price to sales (P/S)
193.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
191.42
Revenue
$7.56M
Gross profit
$7.56M
Operating income
-$217.21M
Net income
-$178.85M
EBIT
-$178.85M
EBITDA
-$175.58M
Free cash flow
-$173.35M
Per share
Balance sheet
Liquidity
EPS
-$2.7
EPS diluted
-$2.7
Free cash flow per share
-$2.61
Book value per share
$10.59
Revenue per share
$0.11
TBVPS
$10.73
Total assets
$739.47M
Total liabilities
$36.49M
Debt
$3.43M
Equity
$702.98M
Working capital
$661.74M
Debt to equity
0
Current ratio
21.67
Quick ratio
21.06
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
-2,322.8%
Gross margin
100%
Net margin
-2,366.1%
Operating margin
-2,873.5%
Return on assets
-22.4%
Return on equity
-23.5%
Return on invested capital
-25.1%
Return on capital employed
-25.3%
Return on sales
-2,366.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLDX stock price
How has the Celldex Therapeutics stock price performed over time
Intraday
-0.5%
1 week
3.92%
1 month
10.72%
1 year
-38.74%
YTD
-12.94%
QTD
8.11%
Financial performance
How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$7.56M
Gross profit
$7.56M
Operating income
-$217.21M
Net income
-$178.85M
Gross margin
100%
Net margin
-2,366.1%
Celldex Therapeutics's operating income has decreased by 34% YoY and by 11% QoQ
Celldex Therapeutics's revenue has increased by 24% YoY and by 8% from the previous quarter
The company's gross profit rose by 24% YoY and by 8% QoQ
Celldex Therapeutics's net income has decreased by 23% YoY and by 13% from the previous quarter
Price vs fundamentals
How does CLDX's price correlate with its fundamentals
Growth
What is Celldex Therapeutics's growth rate over time
Valuation
What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
2.08
P/S
193.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
191.42
CLDX's EPS is down by 10% from the previous quarter but it is up by 6% YoY
The P/B is 49% lower than the 5-year quarterly average of 4.1 and 17% lower than the last 4 quarters average of 2.5
Celldex Therapeutics's equity has decreased by 16% YoY and by 6% from the previous quarter
CLDX's price to sales (P/S) is 55% lower than its 5-year quarterly average of 427.1 and 15% lower than its last 4 quarters average of 227.8
Celldex Therapeutics's revenue has increased by 24% YoY and by 8% from the previous quarter
Efficiency
How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has increased by 34% YoY but it has decreased by 15% from the previous quarter
The ROE has grown by 27% YoY but it has contracted by 19% from the previous quarter
The ROA is up by 26% YoY but it is down by 18% QoQ
CLDX's ROS is down by 5% from the previous quarter
Dividends
What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLDX.
Financial health
How did Celldex Therapeutics financials performed over time
CLDX's quick ratio is down by 33% year-on-year but it is up by 15% since the previous quarter
The current ratio has decreased by 32% YoY but it has increased by 15% from the previous quarter
The debt is 100% lower than the equity
CLDX's debt to equity has dropped by 100% since the previous quarter
The debt has soared by 62% YoY but it has decreased by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.